Lilly and Innovent Report the Global Expansion of their Alliance for Tyvyt (sintilimab)


  • Innovent to receive $200M up front, $825M as development and commercial milestones along with royalties on net sales of the therapy. Both the companies will retain the right to study Tyvyt in combination with other therapies as part of their own clinical programs
  • Lilly will get an exclusive license for the therapy for geographies outside of China and plans to pursue registration of Tyvyt in the US and other territories. Additionally, the two companies are evaluating the Tyvyt as a potential therapy in NSCLC and other cancer indications
  • In 2019, Lilly and Innovent began commercializing Tyvyt in China after receiving approval for r/r classic Hodgkin’s lymphoma post-2L systemic CT and was included in the 2019 Guidelines of Chinese Society of Clinical Oncology for Lymphoid Malignancies

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Science Photo Library

Related News: Innovent and Eli Lilly Report sNDA Acceptance of Tyvyt (sintilimab) Combination Regimen as 1L Therapy in Squamous Non-Small Cell Lung Cancer in China